SLC6A3 and Parkinson disease: Given the significance of epigenetic modifications in PD, therapeutic strategies targeting these modifications (such as epigenetic drugs) have potential to restore normal DAT endocytosis and neuronal differentiation functions, thereby decelerating disease progression.